News | January 01, 2025
Merck inks agreement with Hansoh Pharma for investigational Oral GLP-1 receptor agonist
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
Exclusive global license outside of Greater China for SHR-4849, a Phase 1 DLL3-targeting Topo-I-payload antibody drug conjugate (ADC)
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre
Cenexi is committed to working closely with the ANSM to address the observations
Karkinos is in the business of providing technology-driven, innovative solutions for the early detection, diagnosis, and management of cancer.
Zydus Lifesciences and SBL have mutually decided to extend the date of closing upto March 31, 2025
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
Subscribe To Our Newsletter & Stay Updated
